newsfilter
← Latest News
GlobeNewswire·

Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease

  • The US FDA approved Infilbray (venglustat) on November 18, 2026, as the first oral medicine to treat neurological manifestations of Type 3 Gaucher disease (GD3) in adults & pediatric patients weighing at least 15 kg.
  • Infilbray is a once-daily oral glucosylceramide synthase inhibitor that crosses the blood-brain barrier to target CNS involvement in GD3.
  • Approval was based on the LEAP2MONO phase 3 study, which showed statistically significant superiority over enzyme replacement therapy (imiglucerase) with a p-value of 0.0137.
  • Patients receiving Infilbray demonstrated improvements in cognitive deficits & coordination/balance issues measured by mSARA & RBANS scores at Week 52.
  • The study included adults & pediatric patients aged 12+ who had previously stabilized systemic manifestations with ERT, with 43 patients randomized to Infilbray or imiglucerase.
  • Reported adverse reactions in the primary analysis period included diarrhea (14% vs 0%), splenomegaly (14% vs 0%), nausea (14% vs 5%), depression (10% vs 0%), gastroenteritis (10% vs 0%), & vomiting (10% vs 5%) for Infilbray versus imiglucerase.
  • Infilbray carries warnings for suicidal ideation, lens opacification in pediatric patients, & embryofoetal toxicity.
  • The drug previously received breakthrough therapy, rare pediatric disease, & fast-track designations in the US, plus orphan designation in the EU, US, & Japan.
  • Sanofi plans to pursue additional global regulatory submissions for Infilbray in GD3 during 2026 & 2027.
  • GD3 is a chronic neuronopathic lysosomal storage disorder characterized by systemic decline & neurological symptoms like ataxia & cognitive deficits due to glycosphingolipid accumulation.
Company
Sanofi Winthrop Industrie
Keywords
Paris Stock Exchange:SAN, Sanofi Winthrop Industrie